MY33-3 hydrochloride

For research use only. Not for therapeutic Use.

  • CAT Number: I043592
  • CAS Number: 2204280-42-0
  • Molecular Formula: C16H14ClF6NS2
  • Molecular Weight: 433.86
  • Purity: ≥95%
Inquiry Now

MY33-3 hydrochloride is a potent and selective inhibitor of receptor protein tyrosine phosphatase (RPTP)β/ζ, with an IC50 of ~0.1 μM. MY33-3 hydrochloride also inhibits PTP-1B (IC50 ~0.7 μM). MY33-3 hydrochloride can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction[1][2][3].
MY33-3 hydrochloride (1 μM; pretreated for 5 min) blocks Ethanol-induced activation of TrkA and ALK in SH-SY5Y cells[1].
MY33-3 hydrochloride (0.1-10 μM; 24 h) limits LPS-induced nitrites production and iNos increases in BV2 microglial cells[2].
MY33-3 hydrochloride (60 mg/kg; p.o. on days 3 and 4) reduces ethanol consumption when comparing day 2 with day 3. MY33-3 hydrochloride reduces preference for the ethanol solution on day 3[1].
MY33-3 hydrochloride (i.p.) reverses the Sevoflurane-induced decrease in the discrimination index and impaired motor learning ability[3].


Catalog Number I043592
CAS Number 2204280-42-0
Synonyms

1-[4-(trifluoromethylsulfanyl)phenyl]-N-[[4-(trifluoromethylsulfanyl)phenyl]methyl]methanamine;hydrochloride

Molecular Formula C16H14ClF6NS2
Purity ≥95%
InChI InChI=1S/C16H13F6NS2.ClH/c17-15(18,19)24-13-5-1-11(2-6-13)9-23-10-12-3-7-14(8-4-12)25-16(20,21)22;/h1-8,23H,9-10H2;1H
InChIKey NCXYCGGCHBSQDC-UHFFFAOYSA-N
SMILES C1=CC(=CC=C1CNCC2=CC=C(C=C2)SC(F)(F)F)SC(F)(F)F.Cl
Reference

[1]. Fernández-Calle R, et, al. Pharmacological inhibition of Receptor Protein Tyrosine Phosphatase β/ζ (PTPRZ1) modulates behavioral responses to ethanol. Neuropharmacology. 2018 Jul 15;137:86-95.
 [Content Brief]

[2]. Fernández-Calle R, et, al. Role of RPTPβ/ζ in neuroinflammation and microglia-neuron communication. Sci Rep. 2020 Nov 20;10(1):20259.
 [Content Brief]

[3]. Mao S, et, al. Pleiotrophin Potentiates Sevoflurane Anesthesia-induced Learning Deficits in Mice. J Mol Neurosci. 2022 Jan;72(1):48-55.
 [Content Brief]

Request a Quote